Inspire Medical Systems, Inc. (NYSE:INSP) Holdings Trimmed by Northwest & Ethical Investments L.P.

Northwest & Ethical Investments L.P. reduced its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 5.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,025 shares of the company’s stock after selling 605 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in Inspire Medical Systems were worth $2,044,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of INSP. Smartleaf Asset Management LLC lifted its position in shares of Inspire Medical Systems by 178.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 357 shares of the company’s stock worth $66,000 after purchasing an additional 229 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Inspire Medical Systems in the 3rd quarter worth approximately $1,929,000. Merit Financial Group LLC acquired a new stake in shares of Inspire Medical Systems during the 4th quarter valued at $313,000. Public Employees Retirement System of Ohio grew its holdings in shares of Inspire Medical Systems by 9.4% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 36,361 shares of the company’s stock valued at $7,674,000 after acquiring an additional 3,125 shares in the last quarter. Finally, Jennison Associates LLC acquired a new position in shares of Inspire Medical Systems in the fourth quarter worth $8,821,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on INSP shares. KeyCorp restated an “overweight” rating and issued a $234.00 target price (down previously from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Morgan Stanley lowered their price target on Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating for the company in a research note on Tuesday, February 11th. Stifel Nicolaus cut their price objective on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research report on Tuesday, January 21st. Wells Fargo & Company decreased their target price on shares of Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $260.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, February 11th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $228.82.

Inspire Medical Systems Price Performance

INSP stock opened at $164.39 on Friday. The stock has a market capitalization of $4.88 billion, a price-to-earnings ratio of 95.02, a price-to-earnings-growth ratio of 2.86 and a beta of 1.48. The company has a 50-day moving average of $180.28 and a two-hundred day moving average of $191.32. Inspire Medical Systems, Inc. has a 52-week low of $123.00 and a 52-week high of $257.40.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. Equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In related news, CTO John Rondoni sold 583 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the sale, the chief technology officer now owns 10,424 shares in the company, valued at approximately $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Randy Ban sold 25,584 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the transaction, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. This represents a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,225 shares of company stock worth $4,806,530. Insiders own 4.10% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.